Sigma Planning Corp Has $235,000 Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Sigma Planning Corp cut its stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 5.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 17,785 shares of the company’s stock after selling 950 shares during the period. Sigma Planning Corp’s holdings in Syndax Pharmaceuticals were worth $235,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in SNDX. Assenagon Asset Management S.A. grew its stake in shares of Syndax Pharmaceuticals by 343.0% during the fourth quarter. Assenagon Asset Management S.A. now owns 2,064,456 shares of the company’s stock worth $27,292,000 after purchasing an additional 1,598,428 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. acquired a new stake in shares of Syndax Pharmaceuticals during the third quarter worth $15,165,000. Eventide Asset Management LLC acquired a new position in Syndax Pharmaceuticals in the third quarter valued at about $15,150,000. First Turn Management LLC grew its stake in Syndax Pharmaceuticals by 85.4% in the third quarter. First Turn Management LLC now owns 1,187,165 shares of the company’s stock valued at $22,853,000 after acquiring an additional 546,776 shares during the period. Finally, Sphera Funds Management LTD. grew its stake in Syndax Pharmaceuticals by 25.9% in the third quarter. Sphera Funds Management LTD. now owns 1,034,846 shares of the company’s stock valued at $19,921,000 after acquiring an additional 212,799 shares during the period.

Syndax Pharmaceuticals Stock Performance

SNDX opened at $15.64 on Friday. Syndax Pharmaceuticals, Inc. has a 52-week low of $12.06 and a 52-week high of $25.16. The firm has a market capitalization of $1.33 billion, a PE ratio of -4.31 and a beta of 0.90. The business’s 50-day simple moving average is $14.14 and its 200 day simple moving average is $16.85.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on SNDX. Citigroup boosted their target price on Syndax Pharmaceuticals from $37.00 to $45.00 and gave the company a “buy” rating in a research note on Tuesday, November 19th. HC Wainwright reissued a “buy” rating and issued a $51.00 target price on shares of Syndax Pharmaceuticals in a research note on Tuesday, December 10th. The Goldman Sachs Group boosted their target price on Syndax Pharmaceuticals from $30.00 to $33.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. JPMorgan Chase & Co. boosted their target price on Syndax Pharmaceuticals from $33.00 to $38.00 and gave the company an “overweight” rating in a research note on Thursday, November 21st. Finally, StockNews.com cut Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, November 23rd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $36.20.

Insider Buying and Selling

In other Syndax Pharmaceuticals news, CEO Michael A. Metzger sold 13,288 shares of the company’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $15.50, for a total value of $205,964.00. Following the sale, the chief executive officer now owns 300,121 shares in the company, valued at $4,651,875.50. This represents a 4.24 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Neil Gallagher sold 4,618 shares of the company’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $15.50, for a total value of $71,579.00. Following the completion of the sale, the insider now owns 85,095 shares in the company, valued at $1,318,972.50. This represents a 5.15 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 21,683 shares of company stock worth $336,087. Corporate insiders own 4.10% of the company’s stock.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).